Santa Clara University

Scholar Commons
Bioengineering Senior Theses

Engineering Senior Theses

6-12-2017

Engineering Synthetic Antibody by Expanded
Genetic Code
Elizabeth Batiuk
Santa Clara University, ebatiuk@scu.edu

Tracy Nguyen
Santa Clara University, t1nguyen@scu.edu

Casey Kiyohara
Santa Clara University, ckiyohara@scu.edu

Follow this and additional works at: http://scholarcommons.scu.edu/bioe_senior
Part of the Biomedical Engineering and Bioengineering Commons
Recommended Citation
Batiuk, Elizabeth; Nguyen, Tracy; and Kiyohara, Casey, "Engineering Synthetic Antibody by Expanded Genetic Code" (2017).
Bioengineering Senior Theses. 60.
http://scholarcommons.scu.edu/bioe_senior/60

This Thesis is brought to you for free and open access by the Engineering Senior Theses at Scholar Commons. It has been accepted for inclusion in
Bioengineering Senior Theses by an authorized administrator of Scholar Commons. For more information, please contact rscroggin@scu.edu.

Engineering Synthetic Antibody by
Expanded Genetic Code
By:
Tracy Nguyen, Casey Kiyohara, Elizabeth Batiuk

Senior Design Project Report

Submitted to
The Department of Bioengineering
Of
SANTA CLARA UNIVERSITY

In Partial Fulfillment of the Requirements for the degree of
Bachelor of Science in Bioengineering

Santa Clara, California
Spring 2017

Engineering Synthetic Antibody by Expanded
Genetic Code
Elizabeth Batiuk, Tracy Nguyen, Casey Kiyohara

Department of Bioengineering
Santa Clara University
2017

Abstract
Antibodies are extensively used in research for diagnostic and therapeutic purposes because of
their unrivaled specificity and biomarker binding strengths.1 Currently, monoclonal antibodies are
most commonly used because of their production consistency and purity.1 However, there are
significant ethical and economic challenges associated with producing monoclonal antibodies.1
Synthetic antibodies provide a promising alternative to monoclonal antibodies in both clinical and
research applications.2

Our proposed synthetic antibody system incorporates 3,4-dihydroxy-l-phenylalanine (L-DOPA),
an unnatural amino acid used to increase binding affinity, into a peptide sequence specific for the
prostate specific antigen (PSA), a biomarker for prostate cancer. This addition is predicted to give
the synthetic antibody binding affinity and PSA specificity comparable to existing monoclonal
antibodies while avoiding their drawbacks.3 If successful, our system would replace monoclonal
antibodies for PSA detection as well as be a promising model for developing countless other
synthetic antibodies.
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Introduction
Background, Significance, & Motivation
Antibodies are naturally produced by the immune system to fight off foreign invaders.1 Because
they are specific to a single antigen on a pathogen or infected cell and bind strongly to this
antigen, immune cells are able to locate and destroy these target cells effectively (See Figure 1).1
In order to take advantage of the naturally high strength and specificity of antibody-antigen
interactions, scientific researchers have commercialized antibodies for diagnostic and therapeutic
purposes.1 Diagnostic applications include Western blots and ELISA, which detect the presence
of specific proteins, antibodies, or antigens in a given sample.1 Transducer-based assays are other
diagnostic tools that use antibodies for a wide range of applications, including cancer and
diabetes screening.4 Therapeutic antibodies are used to treat autoimmune disorders,
cardiovascular diseases, and types of cancer.5

Figure 1: Specific Antibody-Antigen Binding

One application of these commercial antibodies is prostate cancer detection. Prostate cancer is
the second most common cancer among men. One in seven men will be diagnosed with prostate
cancer in his lifetime.6 Like most cancer, it is crucial to detect the cancer early, before it
1

metastasizes.6 If detected early enough, 96% of diagnosed men will live another 15 years. There
are two main methods of detecting prostate cancer.6 One indication is an enlarged or abnormal
prostate discovered during a digital rectal exam.6 Another is the level of PSA in the blood.6 As
shown in Figure 2, a healthy prostate secretes a small amount of PSA.6 However, a higher level
of PSA in the blood is seen in those with prostate cancer.6 During routine blood work, the
amount of PSA can be detected using a monoclonal antibody.7

Figure 2. Increased levels of PSA indicate prostate cancer.

Monoclonal antibodies are the gold standard in research and medical applications because of
their inherent consistency and purity.1 However, disadvantages of using monoclonal antibodies
include batch-to-batch variability, ethical concerns, and an expensive and lengthy production
process.1 Synthetic antibodies provide a promising alternative to monoclonal antibodies because
they overcome many of the significant drawbacks of monoclonal antibodies while maintaining
comparable function.8
This project focuses on the development of a synthetic antibody, produced in E. coli, using LDOPA, an unnatural amino acid, incorporation for detection of prostate cancer. The antibody is
specific for PSA, which can indicate prostate cancer at elevated levels.7 This synthetic antibody
2

design offers comparable specificity and binding strength to the monoclonal antibody while also
minimizing the drawbacks involved with production. If successful, this system would replace
monoclonal antibodies for PSA detection, be a promising model for developing countless other
synthetic antibodies, and contribute to the development of personalized medicine in the future.

Literature Review
Design
The basis of this project is a paper by Umeda et al. which details the incorporation of an
unnatural amino acid, L-DOPA, to a peptide (TOP1), GFP reporter protein, and 6-His
purification tag.3 This system, with the exception of the peptide sequence specific for PSA, is the
same as the proposed system of this project. The peptide of the synthetic antibody described in
the paper is specific to the antigen Abelson tyrosine kinase (AbI).3 Similarly, Therriault and
Evans designed a system with a similar design to that of Umeda et al. that targets PSA.14
Although these systems differ from the synthetic antibody in structure and target, the methods
and protocols for unnatural amino acid incorporation and protein expression used in these papers
will be a model and starting point for procedures used throughout this project.

Unnatural Amino Acids
Unnatural amino acids are amino acids not used by ribosomes in cells to make proteins
naturally.8 They can have unique chemistry compared to natural amino acids and have therefore
been proposed as a solution to the inherently weak binding strength between small peptides and
larger proteins when incorporated into the peptide.3 L-DOPA is the unnatural amino acid used by
Umeda et al. to increase the binding strength of a small peptide to a larger protein.3 The
unnatural amino acid performs a redox reaction with a nearby nucleophile in the presence of
sodium periodate, creating a strong covalent bond.3 L-DOPA is particularly useful for unnatural
amino acid incorporation into a recombinant protein because it is orthogonal to natural amino
acids, which ensures correct translation of the peptide including incorporation of L-DOPA.3 LDOPA will therefore be used in this project to increase the binding strength of the synthetic
antibody to PSA using a covalent bond.
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Unnatural amino acids such as L-DOPA can be incorporated into the peptide by introducing into
the cell a mutant tRNA and tRNA synthetase, which are designed to recognize the amber stop
codon (TAG/UAG) on mRNA and incorporate the unnatural amino acid at that location on the
growing peptide.8 The amber stop codon is used because of the three stop codons used naturally,
it is the least frequently used in E. coli (7%) and is rarely is used on essential proteins.8 Using
this stop codon minimizes the likelihood of unnatural amino acid incorporation disrupting
normal cell function and killing the cell.8 The amber stop codon will therefore be used to
incorporate L-DOPA into this synthetic antibody. The pAC-DHPheRS-6TRN plasmid used by
Therriault and Evans contains the genetic code for the mutant tRNA and tRNA synthetase, and
will be used in this project.14

The use of unnatural amino acid incorporation in any protein, peptide, or small molecule system
is a cutting edge technology.9 Researchers and pharmaceutical companies have began using this
technology to engineer antibodies.9 As this process is developed, they experience many obstacles
to synthetic antibody expression and manufacturing.9 These production challenges will be
important considerations in this project as it attempts to develop an accessible and viable product
for companies.9 The solutions other researchers discovered to overcome these challenges will be
helpful for this project.9

One issue faced by researchers incorporating unnatural amino acids at the carboxy terminus of a
gene is truncation of the protein.10 It is very difficult to separate the truncated protein from the
fully-translated protein, and a group of researchers overcame this issue by attaching an intein
protein.10 The intein protein is attached with a tag after the unnatural amino acid amber stop
codon and promotes full translation of the protein.10 This method achieves higher purity and
function and avoids a commonly encountered problem when purifying unnatural amino acids.10
This method would be considered for this project if truncated protein expression becomes an
issue.

Methods and Procedures
One major benefit of this project is avoiding using animals to produce antibodies.8 Instead, E.
coli will be used to produce comparable antibodies.8 E. coli are commonly used for protein
4

production because introducing exogenous recombinant DNA, such as the plasmid for the
synthetic antibody, into them is an established process.18 In addition, by using E. coli, the
synthetic antibody production is able to avoid the ethical concerns of using and killing animals.11
The use of E. coli also limits economic cost, as scaling up production in E. coli is fast due to the
short doubling time of the cells, allowing for high density cultures in bioreactors with simple
growing conditions, rather than requiring large animal facilities.18 These characteristics of E. coli
as a production platform therefore make it ideal for use in this project.

However, since there are big differences between mammalian and E. coli protein production, it is
important to understand the drawbacks to using E. coli.8 These include susceptibility to genetic
mutations as well as the lack of ability to perform post-translational modifications.8 Since the
synthetic antibody used in this project will only be 45 nucleotides, sequencing will be used to
verify the DNA sequence is correct. The synthetic antibody also does not require any posttranslational modifications because of its length, making E. coli a simple and effective
expression platform.

There are three published methods of protein expression with L-DOPA incorporation into
peptides with similar designs to this project’s synthetic antibody.3,16,17 They vary by inducer,
incorporation time, and induction and growth times. To optimize expression and yield of the
synthetic antibody, this project will perform separate but simultaneous experiments using each of
these three methods to identify and develop the most effective expression protocol.

Prostate Cancer Detection
After successfully producing the synthetic antibody, one important aspect of this project will be
assessing whether it is truly comparable to monoclonal antibodies for both diagnostic and
therapeutic applications. Researchers have found that the Kd of PSA to immobilized monoclonal
antibody on a diagnostic chip is 1.1 ± 0.2 nM, giving us a metric by which to assess the binding
affinity of our system.7 In addition, researchers also identified a concentration of PSA (2.6
ng/mL to 4.0 ng/mL) which detects the presence of small prostate cancer without overdiagnosing patients.7 This range is a design specification necessary for the synthetic antibody to
5

achieve target specificity and sensitivity to PSA. Together, these results will determine whether
the synthetic antibody is a viable alternative to monoclonal antibodies.

Critiques of Current Literatures and Technologies
Monoclonal antibodies are extensively used in research.1 However, there are many disadvantages
of using monoclonal antibodies, including the use of animals, a long manufacturing process and
high production costs.1 Antibody production is stimulated in animal immune systems by
injecting them with the target antigen.5 Once the animal’s B-cells start producing antibodies
specific to the antigen, the B-cells are harvested.5 In order to scale up antibody production, the
B-cells are combined with an immortal cell line.5 The resulting mass production of antibodies is
homogenous and pure.5 This entire process can take months to accomplish and is associated with
significant production costs.5 As a result, this leads to increased medical expenses for consumers
and limits accessibility to these technologies.11 In addition, the use of animals raises many ethical
dilemmas and therefore is highly debated in scientific research.11

The primary alternative to monoclonal antibodies is polyclonal antibodies, which have the same
structure and specificity as monoclonal antibodies while requiring less time, skill, and money to
produce.1 However, because they still are produced in animals, they have the same ethical
concerns as monoclonal antibodies.1 In addition, polyclonal antibodies derive from several
different animals and B cell lines at different time points, resulting in batch-to-batch variation
not present in monoclonal antibodies, which stem from a single cell line and are therefore more
consistent.1

Among the other alternatives to monoclonal antibodies scientists are currently developing is
protein scaffolds.12 Protein scaffolds have a general protein framework with specific peptides or
amino acids, which give them specificity to a target, incorporated in them.12 These scaffolds can
be diverse in size, folding, and method of interaction with their targets, giving them more
flexibility than antibodies, which have a constant structure.12 However, because there is very
little data on their immunogenicity and degradability in biological fluids, their potential
applications are currently limited.12

6

Another alternative to monoclonal antibodies currently being explored is aptamers.13 Aptamers
are strands of DNA or RNA which are selected from large libraries to be specific to a certain
target.13 Because they involve no animal use, they avoid the ethical issues of monoclonal
antibodies.13 In addition, because they are made of DNA or RNA, they are more stable than
antibodies when being stored.13 However, aptamers are known to degrade quickly when exposed
to nucleases in biological fluid, limiting their potential applications, particularly for
therapeutics.13

Project Objectives
Based on the strengths and drawbacks of monoclonal antibodies, the overall goal of this project
was established to be designing an alternative that maintained the strengths of monoclonal
antibodies while avoiding their drawbacks as much as possible. The final project objective was
to develop a cost-effective, ethical alternative to monoclonal antibodies that is easier and faster
to manufacture with comparable quality: specificity, sensitivity, and binding strength.

Overall Design
To meet the project objectives, a synthetic antibody produced in E. coli was designed. By being
produced in E. coli, the synthetic antibody has a lower cost, shorter, and more ethical production
process than that of monoclonal antibodies.5,11 The physical design of the synthetic antibody
contains four components: peptide, L-DOPA unnatural amino acid, GFP reporter protein, and 6His purification tag (See Figure 3).

7

Figure 3. Synthetic Antibody Detection and Binding of PSA.
Components of the synthetic antibody include peptide (red), L-DOPA unnatural amino acid (black/red), green
fluorescent protein (green), 6-His tag (purple). Exposure of synthetic antibody-PSA complex to sodium periodate
(detection) allows for formation of a covalent bond (pink) between them.

The 15-amino-acid experimental peptide was designed by a previous Senior Design group,
Therriault and Evans.14 Using open source software developed by University of California, San
Francisco, called Chimera, a library of peptides was screened using several parameters.14 These
parameters include electrostatic interactions and predicted binding affinity that were determined
using the known active site where a commercially available monoclonal PSA antibody binds to
PSA.14 The top peptide candidate that was screened was selected as the experimental peptide for
the design.14 The peptide therefore is predicted to give the synthetic antibody high specificity to
PSA.14

The unnatural amino acid, L-DOPA, was added to the end of the peptide sequence. As discussed
in the literature review, this unnatural amino acid is capable of performing a redox reaction that
creates a covalent bond when exposed to sodium periodate.3 When incorporated into the
synthetic antibody, this covalent bond is expected to form between the synthetic antibody and
PSA once the peptide has specifically targeted the active site of PSA and sodium periodate is
added.3 This covalent bond greatly increases the binding strength of the synthetic antibody to
PSA.3 In order to incorporate this unnatural amino acid, a plasmid designed by Wang et al.,
8

pAC-DHPheRS-6TRN, will be transformed into the E. coli with the synthetic antibody
plasmid.17 This plasmid contains the genetic code for the mutant tRNA and tRNA synthetase
necessary for unnatural amino acid incorporation.17

GFP was added to the synthetic antibody sequence after the unnatural amino acid. GFP is a
commonly used reporter protein in research applications because of its simple visualization
process requiring only UV light.19 It therefore is used to visualize when and how much synthetic
antibody is present during detection. GFP’s straightforward visualization process was also taken
advantage of to verify synthetic antibody expression, as its characteristic green fluorescence is
visible in E. coli correctly producing the synthetic antibody.

The final component of the synthetic antibody, the 6-His tag, was a sequence of six consecutive
histidines at the end of the synthetic antibody sequence. This 6-His sequence is well-established
in the scientific community because its unlikelihood of occurring naturally in another E. coli
protein makes it unique to the protein of interest and therefore ideal for targeting in protein
purification.20 This sequence therefore allows the synthetic antibody to be purified from the E.
coli using affinity chromatography that targets this 6-His tag.
The synthetic antibody sequence was designed so that the ribosomes in the E. coli would first
translate the peptide, followed sequentially by L-DOPA, GFP, and the 6-His tag. This design
allows the ribosome to incorporate the unnatural amino acid, which stresses the ribosome more
than natural amino acid incorporation, before translating the long GFP sequence.21 It has been
hypothesized that translating GFP stresses the ribosome because of its length, and therefore
makes the ribosome more prone to translation errors.21 Because of the expected crucial nature of
the unnatural amino acid to the binding strength, and therefore effectiveness, of the synthetic
antibody, the antibody was designed to minimize the chance of error in unnatural amino acid
incorporation caused by ribosomal stress.

The synthetic antibody sequence was cloned into the pET-28b vector, which then was
transformed into TOP10 competent E. coli cells. The pET-28b vector includes a lac operon and
T7 promoter that allow for regulated expression.14 It also includes a Kan resistance gene which
9

allows for selection of E. coli successfully transformed with this vector.14 Co-transformed into
the E. coli was the second plasmid, pAC-DHPheRS-6TRN (See Appendix A). This plasmid
contains a Tet resistance gene used for selection of E. coli that have been successfully
transformed with this second plasmid.14 Therefore, cells were grown in the presence of both Kan
and Tet in order to select for cells which have been successfully transformed with both plasmids.

Milestones & Expected Results
The first milestone of the project is correct plasmid design. This plasmid provides the E. coli
with the DNA sequence necessary to successfully produce the synthetic antibody. The final
design must incorporate the sequence for all four components of the synthetic antibody adjacent
to a promoter in the pET-28b vector to allow the E. coli to produce the synthetic antibody (See
Appendix B).

The second milestone of the project is successful cloning and transformation. Here, the complete
synthetic antibody sequence must be incorporated into the pET-28b vector at the correct location
so that the cells transformed with these plasmids will be able to produce the synthetic antibody.
The E. coli must then successfully be transformed with this plasmid and the pAC-DHPheRS6TRN plasmid in order to begin producing the synthetic antibody.

Once the E. coli have been successfully transformed with the two plasmids, the third milestone
of the project is successful expression of the synthetic antibody by E. coli. As mentioned in the
literature review, there are several previously established methods of expression of proteins
similar to that designed in this project. All were performed and tested while developing a
successful expression protocol for the synthetic antibody.

After confirming expression, the next milestone is successful purification of the synthetic
antibody. In order to reach a high standard of purity that is comparable to that of monoclonal
antibodies, the synthetic antibody must be purified from all other proteins and other materials
within the E. coli which is producing it. The effectiveness of the purification must be tested,
optimized, and ultimately confirmed to ensure this high level of purity.
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The final milestone of the project is testing of the synthetic antibody. In order to be comparable
to monoclonal antibodies, and therefore a viable alternative, the synthetic antibody must either
meet or exceed the standards of binding strength, specificity, and sensitivity set by monoclonal
antibodies. As described in the literature review, these standards for the anti-PSA monoclonal
antibody are well established, and therefore can be used to test and confirm the efficacy of the
synthetic antibody.

Team Management
To maintain accountability and efficiency throughout the project, various responsibilities were
delegated among the team. Tracy is the liaison with the School of Engineering, handles team’s
finances, and acts as scribe during team and advisory meetings. She is also responsible for
ensuring any deadlines are met. Elizabeth coordinates both meeting and laboratory scheduling
for team and facilitates communications with the advisor, Dr. Zhang. Casey supervises all
writing and editing for the final report and communicates with industry contacts. The laboratory
work, report writing, and presentation development was divided equally among team members.
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Chapter 1: Vector Design & Cloning

Introduction
In designing the cloning of the synthetic antibody sequence into the vector, the synthetic
antibody sequence must incorporate restriction sites that match ones at specific sites in the vector
in order to localize the synthetic antibody sequence near the promoter.

Because there is a Kan resistance gene included in the vector, it is expected that cells which have
been successfully transformed with the pET-28b vector will be resistant to Kan. Of the cells
which are resistant to Kan, some will be selected for DNA sequencing, which will confirm that
the cloning of the synthetic antibody sequence into the vector was successful.

Back-up Plan
If cloning is not accomplished in the allotted time, the oligonucleotide sequences will be sent to a
company to be cloned into pET28b.

Design Logic and Reasoning
Peptide Design
Two sets of forward and reverse single-stranded oligonucleotides of the peptide fragments
coding for the synthetic antibody and negative control were purchased from BioBasic. One set of
oligonucleotides has the amber stop codon (TAG) sequence which would allow for successful
unnatural amino acid incorporation while the other set has a codon for alanine (GCG) in place of
the TAG sequence, serving as the negative control (See Figure 4). This negative control, which
besides this one amino acid is identical to the experimental synthetic antibody, will be used
during the testing phase to confirm that L-DOPA has been incorporated and is increasing the
binding strength of the synthetic antibody as expected. The forward and reverse oligos were
constructed to have 17 overlapping nucleotides to optimize annealing efficiency and specificity.
Each set of oligonucleotides (experimental (TAG) and control (GCG)) were annealed together to
form two double-stranded fragments. Then the double-stranded fragments were extended into
12

complete inserts through a klenow reaction. The klenow reaction was selected over a PCR
reaction due to its high efficiency of extension for short fragments such as this peptide, which is
less than 150 base pairs.

Figure 4. Experimental and control nucleotide design sequence alignment. Experimental sequence is specific for
PSA and contains 3’ TAG codon for L-DOPA incorporation. Control peptide serves as a negative control for LDOPA incorporation and contains a codon for alanine.

Expression Vector Selection
pET28b-GFP was selected as the expression vector because it contains an enhanced GFP. It also
contains a 6-His that will be used during protein purification by affinity chromatography. The
oligonucleotides were cloned on the 3’ end of the T7 promoter and 5’ of the 6-His and GFP (See
Figure 5).

Figure 5. Step-by-step of double digestion of vector to insert peptide.
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Materials and Methods
pET28b-PI-TAG-GFP Vector Construction
The peptide predicted to be specific for PSA was selected through an in silico screen as
described by Therriault and Evans.1 Oligonucleotides containing experimental or control
peptides, restriction sites, and flanking sequences were ordered as two overlapping fragments
(BioBasic), annealed, and extended using the large polymerase I, large (klenow) fragment for 15
minutes at 25℃ (NEB, See Appendix E Table 1). Products were run on a 2% agarose gel for
verification. Oligonucleotides were purified by QIAquick PCR Purification Kit (Qiagen) and
double digested with restriction endonucleases EcoRI-HF and XbaI (NEB) for 10 hours at 37℃
(See Appendix E Table 2). Products were purified (Qiagen) prior to ligation.

pET28b-GFP contains a 6-His and genes for Kan resistance and GFP. 5 mL cultures were grown
in LB (Teknova) with 50 μg/mL Kan (Teknova) and plasmids were purified by QIAprep Spin
Miniprep Kit (Qiagen). Plasmids were double digested for four hours at 37℃ (See Appendix E
Table 3) and run on 1% agarose gel, gel extracted, and purified using the QIAquick Gel
Extraction Kit (Qiagen). 5’ DNA ends were dephosphorylated using CIP (NEB, See Appendix E
Table 4) and subsequently purified (Qiagen) prior to ligation in order to minimize self-ligation of
the vector without incorporation of the insert.

Ligations (one set for each the control and experimental oligonucleotides) were performed using
T4 DNA Ligase (Promega) at 1:1, 1:2 and 1:10 ratios of pET28b-GFP:oligonucleotide (See
Appendix E Table 5) and transformed into TSS TOP10 chemically competent cells (as described
in Chung et al.) before being plated onto LB-agar (MP Biomedicals LLC) plates containing 50
µg/mL Kan.15 Colonies were picked and grown in 5 mL LB + 50 µg/mL Kan cultures. DNA was
purified (Qiagen) and sequenced (Sequetech) using the T7 primer.

14

Results

Figure 6. 1% agarose gel for pET28b-GFP vector cut (left two bands) and uncut (right band) by EcoRI-HF
and Xba1 restriction enzymes. Visualized using Fisher Scientific Transilluminator and 0.5 µg/mL EtBr. Ladder
(far right) was Quick-load 1kb DNA ladder (NEB).

15

Figure 7. Sequence Alignment of Experimental (Query) and Control (Sbjct) Vectors. Highlighted in red is the
one amino acid difference between the two sequences.

16

Figure 8. Chromatograms of Experimental (A) and Control (B) sequences at location of the amino acid
difference.

Discussion
As seen in Figure 6, the vector was successfully double digested, however after sending the
vectors to sequencing after cloning, the vectors were confirmed to have self-ligated instead of
incorporating the peptide and L-DOPA. Varied time and order of digestion, and time of CIP
reaction were performed. Unfortunately, due to time constraints, the designed vectors (one for
control and one for experimental) were constructed at Epoch Life Science, Inc (Missouri City,
TX). The vectors were sequenced and results are shown in Appendix C and Appendix D. Figure
7 shows the nucleotide alignment between the experimental and control vector sequence to
verify they are correct and differ at the last codon of the peptide. Figure 8 shows the
chromatogram of both the experiment and control peptides. The little background noise and
clean peaks show the clones are correct and pure. The confidence that the vectors are pure and
accurate is necessary before moving on to the next step of the project, synthetic and control
antibody expression.

17

Chapter 2: Protein Expression

Introduction
In order to maximize efficiency of transformation, a stepwise transformation was performed,
with cells successfully transformed with one plasmid then being made competent before being
transformed with the second plasmid (See Figure 9). The pAC-DHPheRS-6TRN plasmid was
transformed into E. coli first to increase transformation efficiency and minimize toxicity
concerns caused by the mutant tRNA and tRNA synthetase. In addition, transformation of the
pAC-DHPheRS-6TRN plasmid first allows for the potential future creation of a commercialized
kit, containing competent cells into which a plasmid for any synthetic antibody containing LDOPA can be transformed and immediately expressed.

Figure 9. Sequential co-transformation of pET28b+P1+GFP and pAC-DHPheRS-6TRN

In this step, confirmation of successful expression is performed by taking advantage of the
design of the synthetic antibody. Because the design includes GFP, cells which are successfully
producing synthetic antibody are expected to have a visual green fluorescence in the culture.
Therefore, during expression of the synthetic antibody, the E. coli cultures were observed under
UV light to confirm that there is this indicative green fluorescence.

18

Back-up Plan
Although there are a few different aspects of expression where issues may arise, the methods of
this project were designed to minimize those risks. In order to ensure expression, three different
established L-DOPA protein expression methods were separately used to optimize yield and
expression.3,16,17 Since L-DOPA is easily oxidized, the pH was carefully controlled during
expression. As discussed previously, expression of proteins with unnatural amino acids can result
in truncated protein. Since GFP is at the carboxy terminus of the synthetic antibody, a truncated
synthetic antibody would not fluoresce during expression. An intein protein could be attached to
minimize truncation.10 If these issues or others are experienced and not resolved in a timely
manner, the experimental and control synthetic vectors will be sent to a company to be
expressed.

Materials and Methods
pAC-DHPheRS-6TRN Competent Cell Preparation
pAC-DHPheRS-6TRN contains genes for the mutant tRNA and mutant tRNA synthetase as well
as the Tet resistance gene. pAC-DHPheRS-6TRN was transformed into calcium chloride
competent TOP10 E. coli cells using a high efficiency chemical transformation protocol (NEB).
Cells were plated on LB-agar + 10 µg/mL Tet (Teknova). A single colony was picked and grown
in LB broth + 10 µg/mL Tet and a glycerol stock was prepared. Chemically competent cells from
this glycerol stock were made using the TSS protocol.15

Co-Transformation of pET28b-PI-TAG-GFP
5 mL cultures of pET28b-PI-TAG-GFP and pET28b-PI-GCG-GFP (Epoch Life Science, Inc)
were grown overnight before plasmids were purified (Qiagen) and transformed into pACDHPherRS-6TRN TOP10 competent E. coli cells and plated on LB-agar + 30 µg/mL Kan + 25
µg/mL Tet plates.

Antibody Expression Protocol #1
This method was adapted from Zhang et al.16 Co-transformed colonies (4 from TAG, 4 from
GCG) were picked from LB-agar (Teknova, MP Biomedicals LLC) plates and grown in 2.0 mL
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LB + 30 µg/mL Tet and 60 µg/mL Kan, shaking in the dark at 37℃ overnight. 25% glycerol
stocks were made for each cell line and stored at -80℃. 500 µL of overnight culture was added
to 125 mL of M9 Medium Broth (Amresco) with 30 µg/mL Kan + 25 µg/mL Tet and 1 mM LDOPA (Sigma-Aldrich) and grown in the dark in a shaking incubator at 37℃ until OD600
reached 0.5. The pH of the culture was maintained at pH 6.5 during growth. At OD600 0.5, 0.2%
L-Arabinose (Sigma-Aldrich) was added and cultures were grown for 4 hours at 37℃. Cultures
were harvested by centrifuge at 5,000 x g for 11 minutes at 4℃, supernatant was decanted and
pellets were stored at -80℃.

Antibody Expression Protocol #2
This method was adapted from Wang et al.17 Co-transformed colonies (4 from TAG, 4 from
GCG) were picked from LB-agar plates and grown in 2.0 mL LB + 30 µg/mL Tet and 60 µg/mL
Kan, shaking in the dark at 37℃ overnight. 25% glycerol stocks were made for each cell line and
stored at -80℃. 500 µL of overnight culture was added to 125 mL of M9 Medium Broth with 30
µg/mL Kan + 25 µg/mL Tet and 1 mM L-DOPA (Sigma-Aldrich) and grown in the dark in a
shaking incubator at 37℃ until OD600 reached 0.5. The pH of the culture was maintained at pH
6.5 during growth. At OD600 0.5, 1 mM IPTG was added and cultures were grown for 5 hours at
37℃. Cultures were harvested by centrifuge at 5,000 x g for 11 minutes at 4℃, supernatant was
decanted and pellets were stored at -80℃.

Antibody Expression Protocol #3
This method was adapted from Umeda et al.3 Co-transformed colonies (4 from TAG, 4 from
GCG) were picked from LB-agar plates and grown in 2.0 mL LB + 30 µg/mL Tet and 60 µg/mL
Kan, shaking in the dark at 37℃ overnight. 25% glycerol stocks were made for each cell line and
stored at -80℃. 500 uL of overnight culture was added to 125 mL of M9 Medium Broth with 30
µg/mL Kan + 25 µg/mL Tet and grown in the dark in a shaking incubator, at 37℃ until OD600
reached 0.6. During this time, the pH of the culture was maintained at pH 6.5. At OD600 0.6, 1
mM IPTG was added to the cultures, which then were incubated at 30℃ for 6 hours. Cultures
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were viewed after 4 hours using a Fisher Scientific Transilluminator. Cultures were harvested by
centrifuge at 5,000 x g for 11 minutes at 4℃, supernatant was decanted and pellets were stored at
-80℃.

Results
Co-Transformation of pET28b+PI+TAG and pAC-DHPheRS-6TRN

Figure 10. Transformed E. coli + pAC-DHPheRS-6TRN plated on LB + agar + 10 µg/mL Tet+ 50 µg/mL Kan
+ 0.2% arabinose. TOP10 E. coli + pAC-DHPheRS-6TRN transformed with experimental synthetic antibody
plasmid (A), control synthetic antibody plasmid (B), no plasmid (C), plasmid with no synthetic antibody (D).

Figure 11. Experimental (A), control (B), and no GFP (C) cultures using antibody expression protocol #3
visualized under UV light after 4 hours of synthetic antibody expression.

Discussion
As shown in Figure 10, the co-transformation of pET28b+PI+TAG and pET28b+PI+GCG
(control) into TOP10 competent cells containing pAC-DHPheRS-6TRN was successful. Plates C
and D serve as negative controls. Plate C was plated with cells transformed with water and plate
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D was plated with cells transformed with a plasmid without Tet resistance, a quality control for
the plates.

For the cultures using expression protocol #3, the cultures were placed in UW light 4 hours after
induction of synthetic antibody production with IPTG (Figure 11). Compared to the culture with
cells not producing the synthetic antibody, which therefore were not producing GFP, the
experimental and control cultures had a distinct green color under the UV, indicating that they
were producing GFP and therefore the synthetic antibody. These results indicate successful
expression of the synthetic antibody within the E. coli cells.
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Chapter 3: Protein Purification

Introduction
Before testing the functionality of the synthetic antibodies, they must first be purified. This was
done by manual affinity chromatography using 6-His. After lysing the cells, the proteins were
separated and passed through a column containing Ni-NTA beads. Only the synthetic antibody
will bind to the beads allowing for the other proteins to be removed. The synthetic antibody was
then eluted as a pure sample from the beads.

Back-up Plan
Although manual affinity chromatography is a well-defined purification procedure, if any issues
arise, FPLC will be used. This automated process produces pure and large quantities of proteins.
However, it would be time consuming to troubleshoot and learn how to use this machine.
Purification can also be contracted out to a company if necessary.

Materials and Methods
A separate purification was performed for each individual cell type and growing condition. E.
coli pellets were thawed in a hot water bath for approximately 10 minutes. Each pellet was then
resuspended in 5 mL of lysis buffer (PBS + 1 mg/mL lysozyme + 0.5 mM PMSF + 10 mM
imidazole) and left on ice for 20 minutes. The cells were then sonicated 6 times at 30%
alternating between 6 seconds on and 6 seconds off. The lysate was then centrifuged at 4℃ and
16,000 rpm for 40 minutes. 1 mL sample of the supernatant was taken and stored in -20℃.

While centrifuging, one set of HisPurTM Ni-NTA beads (Thermo Fisher Scientific) specific to
the 6-His tag was prepared for each culture by resuspending 125 µL of the beads (1:1000 ratio of
volume of beads:volume of initial culture) in 5 mL of PBS + 25 mM imidazole before being
centrifuged for 4 minutes at 2000 rpm. After pouring out the supernatant, this process was
repeated 4 times.
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The supernatant of the centrifuged lysate solutions was then used to resuspend the Ni-NTA beads
(one culture per set of beads). Binding of the proteins to the beads was then done by rocking the
resuspended beads at 4℃ for 1 hour before centrifuging them for 4 minutes at 2000 rpm at 4℃.
1 mL of the flow-through after binding was then sampled and the rest was discarded. The beads
were then washed 5 times. In these wash steps, the beads were resuspended in PBS + 25 mM
imidazole wash buffer, rocked for 20 minutes at 4℃, then centrifuged at 2000 rpm at 4℃ for 4
minutes before the supernatant was sampled and discarded.

For elution, the beads were resuspended in 200 µL of PBS + 250 mM imidazole, rocked for 20
minutes, and centrifuged at 2000 rpm for 4 minutes. The supernatant, which ideally contains the
target protein, was then extracted and stored at -20℃. Two elution steps were performed for each
culture.

Samples of lysate, flow-through, initial wash step, and elution for each purification were run on a
SDS-PAGE (Genscript) at 120 volts for 60 minutes. Gels were visualized and imaged using
LabSafe GEL Blue (G-Biosciences).

Results

Figure 12. SDS-PAGE of purification Left image shows synthetic antibody and right shows control antibody. Lane
one is PageRuler Prestained Protein Ladder (ThermoFisher Scientific). Lane two is sample of supernatant after cells
were lysed and centrifuged. Lane three is flow-through sample after binding to column. Lane four is sample after
first wash is performed. Lane five is sample of first elution.
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Discussion
Both the control and experimental SDS-PAGEs show a large amount of proteins of many sizes in
the supernatant lane, which is expected as this was a sample of all of the proteins in the E. coli.
Many of these proteins did not bind to the beads and were therefore also in the flow-through,
which would also be expected because the Ni-NTA HisPur beads which were used were specific
to the 6-His unique to the synthetic antibody, preventing other proteins without this tag from
binding. The wash lanes indicate that there was some nonspecific binding of non-synthetic
antibody proteins to the beads, which were then removed by the wash steps as the higher
concentration of imidazole allowed it to competitively bind to the beads.

The elution lanes show a strong band at approximately 27 kDa, which is the predicted size of our
synthetic antibody. Therefore, the antibody has essentially been purified. However, there are
some remaining bands of various weights shown in the elution lanes, indicating that there is still
some non-specific binding occurring, which would need to be eliminated through optimization of
the protein purification protocol. This optimization would most likely involve adjustments in the
wash steps, such as increasing the concentration of imidazole (increasing its ability to compete
with other proteins to bind to the beads) or a greater number of washes.
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Chapter 4: Conclusion
Testing & Analysis
The next steps of this project will be to analyze the functionality of the synthetic antibody. To
replace the monoclonal antibody used for PSA detection, the synthetic antibody must have
comparable functionality. The previous results show the experimental and control synthetic
antibodies were correctly expressed. Next, the synthetic antibodies will be tested to ensure
proper L-DOPA incorporation in the experimental synthetic antibody. This will be done by
measuring the K of both synthetic antibodies to PSA using ITC. The K value will indicate the
d

d

binding affinity between the synthetic antibody and PSA. Since the incorporation of L-DOPA
allows the experimental synthetic antibody to form a covalent bond to PSA, the binding strength
will be much greater than the control synthetic antibody. The values will also be compared to the
binding strength of the currently used monoclonal antibody for PSA detection, 1.1 ± 0.2 nM. The
experimental synthetic antibody must have, at most, the same K value to be comparable to the
d

anti-PSA monoclonal antibody.

Others metrics that will be tested and compared to those of the anti-PSA monoclonal antibody
are specificity and sensitivity. It is crucial that the synthetic antibody is specific to PSA so that
prostate cancer detection tests are precise and accurate. Both specificity and sensitivity will be
tested using a Western blot. PSA samples will be titrated; then the specificity and sensitivity of
the experimental synthetic antibody will be measured and compared to the anti-PSA monoclonal
antibody. Currently, levels of PSA below 2.5 ng/mL are considered to be within the normal
range. Blood concentrations of PSA between 2.5 ng/mL and 4.0 ng/mL are an indication of
7

prostate cancer. The synthetic antibody must be able to clearly indicate the differences between
7

these two ranges.

The design of the synthetic antibody predicts the specificity, sensitivity, and binding strength to
be at least as effective, if not better than, the standards set by the currently used anti-PSA
monoclonal antibody. However, these specifications must be tested to ensure incorporation of LDOPA during expression and comparable functionality to currently used technologies.
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Summary and Future Applications
This project focuses on creating a synthetic antibody for PSA measurement for prostate cancer
detection. If testing follows theoretical values, this antibody can replace the currently used antiPSA monoclonal antibody. As previously mentioned, antibodies are used extensively in research
and medicine and prostate cancer detection is just one of numerous applications. This project
evaluates the synthetic antibody design as a possibility to replace other monoclonal antibodies.
Synthetic antibodies avoid many of the drawbacks of monoclonal antibodies, including batch-tobatch variability, ethical concerns, and an expensive and long production process.

1

The results from this project show successful design and cloning of the synthetic antibody. In
addition, it was successfully and produced in and purified from E. coli. Future testing would
verify the incorporation and functionality of the synthetic antibody compared to the currently
used monoclonal antibody for prostate cancer detection. This proof of concept is a model for
future synthetic antibodies to be produced to essentially any other protein target. The advantages
of this modular synthetic antibody design would make it desireable to researchers as well as
clinicians and could become the new gold standard antibodies in industry. From the results
obtained from this project, synthetic antibodies for diagnostic and therapeutic purposes are a
promising technology, however, future testing is still required.
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Chapter 5: Ethical Concerns
Monoclonal antibodies are currently widely used in both industry and research settings, and as a
result, they are an established and well-known product due to their high specificity and binding
strength. However, the production process of the monoclonal antibodies has two main ethical
concerns including animal use as well as the expensive nature of the process leading to concerns
regarding fair access of patients to medical advancements.

The use of live animals such as mice and rabbits as a hosts of production of monoclonal
antibodies is an ethical concern because it requires invoking their immune system prior to the
extraction of their blood. This process is harmful to the animals and raises concerns regarding
animal abuse. Overall, the use of animals as hosts for this production method is life-threatening
to the animals and usually leads to their death. In comparison, synthetic antibodies do not use
animals such as mice and rabbits as hosts, instead E. coli bacteria are used.

Another ethical concern to monoclonal antibodies is their high cost as a result of their production
process. The high cost of this technology can lead to minimal access to those who cannot afford
to have access to it. Monoclonal antibodies are extensively used in research for medical
advancements that could benefit patients, and the high-cost can deter researchers from using it
and can lead to delays in new technology. Similarly, monoclonal antibodies are used in prostate
cancer blood test and their high cost increases the cost of the test. In response, health insurance
companies are reluctant to pay for it if the patient does not show any signs of prostate cancer. It
is necessary for these tests to be done early regardless of symptoms because the lack of early
detection contributes to many cancer patient deaths.
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Chapter 6: Engineering Standards and Realistic Constraints
For all engineering designs, there are many considerations that must be taken into account prior
to creating and implementing the design. The following factors will be discussed in terms of how
the design and stakeholders that are involved will be impacted.

Economic
Like any other product, economic factors are necessary to take into consideration in terms of
how much resources are needed to fund as well as implement the design and the overall cost of
the product for it to be used by its intended audience. For this design, it was necessary to propose
a budget for funding that was enough to carry out all of the experiments. Typical antibody
production requires an immense amount of resources as well as animal facilities which can drive
up costs and increase the amount of labor that is needed. Instead, the synthetic antibody
production is performed at a smaller scale for testing and the host that is used for production, E.
coli, is much cheaper and easier to scale up. Not only for the practicality of this project, but for
future implementation, the synthetic antibody design described in this paper is a cheaper
alternative than commercial monoclonal antibody production which will benefit researchers and
patients who would have increased accessibility due to the lower cost of this technology.

Ethical
There are many ethical concerns with regards to who the stakeholders of this project will be.
These stakeholders include who will be producing the synthetic antibody, who will be using the
synthetic antibody such as researchers, academic institutions, and industry members, and lastly
who would be benefitting or affected by the technology that is developed either from the indirect
or direct usage of the synthetic antibody. As elaborated in Chapter 5, there are ethical concerns
with regards to animal production as well as high costs that would limit the accessibility to the
benefits of this technology. For this design, there are no animals used in the production process
and the overall production is much cheaper than the commercial production methods currently
used. As a result, this would eliminate ethical conflicts for those who are working to produce the
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synthetic antibody, those who are concerned about animal mistreatment, and those who would be
deterred from using antibodies due to their high costs.

A big-picture concern of this design could be if it is used a biological weapon due to the ease of
the design. The screening method could be used to screen for a peptide that can target and cause
disease or a physiological disorder. Then it could be implemented and produced using the
production method described in this paper in a small laboratory setting without any regulations.
It is necessary to be aware of this ethical concern; however, the screening process as a well as
weaponizing of the synthetic antibody requires extensive knowledge that is not as straightforward as the application of the design in this paper which is to target PSA, a well-known
biomarker. However engineering as well as ethical standards should be upheld by those who are
producing it to cause no harm to any of the stakeholders.

Social
Social responsibility towards all stakeholders is necessary to be taken into consideration for this
project. Stakeholders who have limited access to the benefits of monoclonal antibody technology
are those who are financially deterred as a result of high prices that would prevent insurance
companies from subsidizing the cost of the application such as prostate cancer blood tests. A
method that could allow for equal access to synthetic antibody is by reducing the overall cost of
it. For example if the synthetic antibody is used for drug development, it would substantially
reduce the cost of research due to failed attempts or multiple iterations that are required during
development. This would lead to a reduced cost of the drug, and would allow for increased
access to it for those who previously did not have access due to its high cost.

Manufacturability
For almost all designs, it is necessary that the design is validated to work on a smaller-scale
before scaling it up in order to conserve resources. However, scaling-up can lead to other
challenges and complications. One of the challenges of monoclonal antibody production is that
scaling-up requires larger animal facilities, and there is also a potential for variations as a well as
functionality in the final product due to it coming from multiple animal hosts.14 This can lead to
inconsistencies in quality control.14
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This manufacturability concern can be overcome in the synthetic antibody design because the
production platform is E. coli rather than multiple animal hosts. Scaling-up with E.coli using
bioreactors has been documented in literature and has been well-studied so this design has a very
real potential for scaling-up to the level of commercial usage with consistent quality.18

Health & Safety
It is necessary to ensure the health and safety of not only the members of this project but also
other stakeholders who would be using this product. To produce the synthetic antibody, all
members of the team were qualified to work in the lab by undergoing an exam to ensure that
Santa Clara University Laboratory Safety Protocol and Procedures were understood. All
members have also previously worked on protein production and purification and so proper lab
techniques as well as handling of hazardous material have been established, and as a result,
safety in the lab for all members can be ensured.

For the stakeholders who would be using the product it is necessary that it is appropriately used
for its intended purpose. An example of this would be to use the prostate specific synthetic
antibody for the purpose of detection of PSA rather than for detecting another biomarker. This
will ensure safety and accuracy for the patients who would be receiving the results.
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Appendix
Appendix A: pAC DHPheRS-6TRN plasmid map

34

Appendix B: Experimental Vector
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Appendix C. Experimental Vector: pET28-P1+GFP+His Sequencing
Information
LOCUS

GS61233-1 pET28-P1+GFP+His

5977 bp ds-DNA circular SYN 25-Apr-2017

DEFINITION .
ACCESSION .
VERSION

.

KEYWORDS

GS61233-1 pET28-P1+GFP+His

SOURCE

synthetic DNA construct

ORGANISM synthetic DNA construct
REFERENCE 1 (bases 1 to 5977)
AUTHORS .
TITLE

Direct Submission

FEATURES

Location/Qualifiers

source

1..5977
/organism="synthetic DNA construct"
/mol_type="other DNA"

terminator

26..73

/note="T7 terminator"
/note="transcription terminator for bacteriophage T7 RNA
polymerase"
/note="color: #ffffff"
CDS

complement(140..157)
/codon_start=1
/product="6xHis affinity tag"
/note="6xHis"
/note="color: #cc99b2"

/translation="HHHHHH"
gene

173..949

/note="P1+GFP+His"
/note="color: #a6acb3; direction: RIGHT"
CDS

complement(179..892)
/codon_start=1
/product="GFP variant optimized for excitation by UV light"
/label="GFPuv"
/note="GFPuv"
/note="color: #05fd14"

/translation="MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLK
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FICTTGKLPVPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDG
NYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQKNGIKA
NFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLE
FVTAAGITHGMDELYK"
protein_bind

952..976

/bound_moiety="lac repressor encoded by lacI"
/note="lac operator"
/note="The lac repressor binds to the lac operator to
inhibit transcription in E. coli. This inhibition can be
relieved by adding lactose or
isopropyl-beta-D-thiogalactopyranoside (IPTG)."
/note="color: #31849b"
promoter

complement(977..995)

/note="T7 promoter"
/note="promoter for bacteriophage T7 RNA polymerase"
/note="color: #ffffff; direction: LEFT"
promoter

1304..1381

/gene="lacI"
/note="lacI promoter"
/note="
"
/note="color: #ffffff; direction: RIGHT"
CDS

1382..2464
/codon_start=1
/gene="lacI"
/product="lac repressor"
/note="lacI"
/note="The lac repressor binds to the lac operator to
inhibit transcription in E. coli. This inhibition can be
relieved by adding lactose or
isopropyl-beta-D-thiogalactopyranoside (IPTG)."
/note="color: #993366"

/translation="MKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAEL
NYIPNRVAQQLAGKQSLLIGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGV
EACKAAVHNLLAQRVSGLIINYPLDDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSH
EDGTRLGVEHLVALGHQQIALLAGPLSSVSARLRLAGWHKYLTRNQIQPIAEREGDWSA
MSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAITESGLRVGADISVVGYDDTEDSSC
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YIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSLVKRKTTLAPNTQTASPR
ALADSLMQLARQVSRLESGQ"
CDS

3273..3464
/codon_start=1
/gene="rop"
/product="Rop protein"
/note="rop"
/note="color: #993366"

/translation="MTKQEKTALNMARFIRSQTLTLLEKLNELDADEQADICESLHDHA
DELYRSCLARFGDDGENL"
rep_origin

complement(3894..4482)

/direction=LEFT
/note="ori"
/note="high-copy-number colE1/pMB1/pBR322/pUC origin of
replication"
/note="color: #ffff00"
CDS

4604..5419
/codon_start=1

/gene="aph(3')-Ia"
/product="aminoglycoside phosphotransferase"
/note="KanR"
/note="confers resistance to kanamycin"
/note="color: #ccffcc"
/translation="MSHIQRETSCSRPRLNSNMDADLYGYKWARDNVGQSGATIYRLYG
KPDAPELFLKHGKGSVANDVTDEMVRLNWLTEFMPLPTIKHFIRTPDDAWLLTTAIPGK
TAFQVLEEYPDSGENIVDALAVFLRRLHSIPVCNCPFNSDRVFRLAQAQSRMNNGLVDA
SDFDDERNGWPVEQVWKEMHKLLPFSPDSVVTHGDFSLDNLIFDEGKLIGCIDVGRVGI
ADRYQDLAILWNCLGEFSPSLQKRLFQKYGIDNPDMNKLQFHLMLDEFF"
rep_origin

complement(5511..5966)

/direction=LEFT
/note="f1 ori"
/note="f1 bacteriophage origin of replication; arrow
indicates direction of (+) strand synthesis"
/note="color: #ffff00"
ORIGIN
1 atccggatat agttcctcct ttcagcaaaa aacccctcaa gacccgttta gaggccccaa
61 ggggttatgc tagttattgc tcagcggtgg cagcagccaa ctcagcttcc tttcgggctt
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121 tgttagcagc cggatctcag tggtggtggt ggtggtgctc gagtgcggcc gcaagctttt
181 tgtagagctc atccatgcca tgtgtaatcc cagcagcagt tacaaactca agaaggacca
241 tgtggtcacg cttttcgttg ggatctttcg aaagggcaga ttgtgtcgac aggtaatggt
301 tgtctggtaa aaggacaggg ccatcgccaa ttggagtatt ttgttgataa tggtctgcta
361 gttgaacgga tccatcttca atgttgtggc gaattttgaa gttagctttg attccattct
421 tttgtttgtc tgccgtgatg tatacattgt gtgagttata gttgtactcg agtttgtgtc
481 cgagaatgtt tccatcttct ttaaaatcaa taccttttaa ctcgatacga ttaacaaggg
541 tatcaccttc aaacttgact tcagcacgcg tcttgtagtt cccgtcatct ttgaaagata
601 tagtgcgttc ctgtacataa ccttcgggca tggcactctt gaaaaagtca tgccgtttca
661 tatgatccgg ataacgggaa aagcattgaa caccataaga gaaagtagtg acaagtgttg
721 gccatggaac aggtagtttt ccagtagtgc aaataaattt aagggtaagt tttccgtatg
781 ttgcatcacc ttcaccctct ccactgacag aaaatttgtg cccattaaca tcaccatcta
841 attcaacaag aattgggaca actccagtga aaagttcttc tcctttactc atgaattcct
901 agcaggtcca gcaatgatgt tcaatgcaat acgccacgca cattctagag gggaattgtt
961 atccgctcac aattccccta tagtgagtcg tattaatttc gcgggatcga gatctcgatc
1021 ctctacgccg gacgcatcgt ggccggcatc accggcgcca caggtgcggt tgctggcgcc
1081 tatatcgccg acatcaccga tggggaagat cgggctcgcc acttcgggct catgagcgct
1141 tgtttcggcg tgggtatggt ggcaggcccc gtggccgggg gactgttggg cgccatctcc
1201 ttgcatgcac cattccttgc ggcggcggtg ctcaacggcc tcaacctact actgggctgc
1261 ttcctaatgc aggagtcgca taagggagag cgtcgagatc ccggacacca tcgaatggcg
1321 caaaaccttt cgcggtatgg catgatagcg cccggaagag agtcaattca gggtggtgaa
1381 tgtgaaacca gtaacgttat acgatgtcgc agagtatgcc ggtgtctctt atcagaccgt
1441 ttcccgcgtg gtgaaccagg ccagccacgt ttctgcgaaa acgcgggaaa aagtggaagc
1501 ggcgatggcg gagctgaatt acattcccaa ccgcgtggca caacaactgg cgggcaaaca
1561 gtcgttgctg attggcgttg ccacctccag tctggccctg cacgcgccgt cgcaaattgt
1621 cgcggcgatt aaatctcgcg ccgatcaact gggtgccagc gtggtggtgt cgatggtaga
1681 acgaagcggc gtcgaagcct gtaaagcggc ggtgcacaat cttctcgcgc aacgcgtcag
1741 tgggctgatc attaactatc cgctggatga ccaggatgcc attgctgtgg aagctgcctg
1801 cactaatgtt ccggcgttat ttcttgatgt ctctgaccag acacccatca acagtattat
1861 tttctcccat gaagacggta cgcgactggg cgtggagcat ctggtcgcat tgggtcacca
1921 gcaaatcgcg ctgttagcgg gcccattaag ttctgtctcg gcgcgtctgc gtctggctgg
1981 ctggcataaa tatctcactc gcaatcaaat tcagccgata gcggaacggg aaggcgactg
2041 gagtgccatg tccggttttc aacaaaccat gcaaatgctg aatgagggca tcgttcccac
2101 tgcgatgctg gttgccaacg atcagatggc gctgggcgca atgcgcgcca ttaccgagtc
2161 cgggctgcgc gttggtgcgg atatctcggt agtgggatac gacgataccg aagacagctc
2221 atgttatatc ccgccgttaa ccaccatcaa acaggatttt cgcctgctgg ggcaaaccag
2281 cgtggaccgc ttgctgcaac tctctcaggg ccaggcggtg aagggcaatc agctgttgcc
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2341 cgtctcactg gtgaaaagaa aaaccaccct ggcgcccaat acgcaaaccg cctctccccg
2401 cgcgttggcc gattcattaa tgcagctggc acgacaggtt tcccgactgg aaagcgggca
2461 gtgagcgcaa cgcaattaat gtaagttagc tcactcatta ggcaccggga tctcgaccga
2521 tgcccttgag agccttcaac ccagtcagct ccttccggtg ggcgcggggc atgactatcg
2581 tcgccgcact tatgactgtc ttctttatca tgcaactcgt aggacaggtg ccggcagcgc
2641 tctgggtcat tttcggcgag gaccgctttc gctggagcgc gacgatgatc ggcctgtcgc
2701 ttgcggtatt cggaatcttg cacgccctcg ctcaagcctt cgtcactggt cccgccacca
2761 aacgtttcgg cgagaagcag gccattatcg ccggcatggc ggccccacgg gtgcgcatga
2821 tcgtgctcct gtcgttgagg acccggctag gctggcgggg ttgccttact ggttagcaga
2881 atgaatcacc gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaacg tctgcgacct
2941 gagcaacaac atgaatggtc ttcggtttcc gtgtttcgta aagtctggaa acgcggaagt
3001 cagcgccctg caccattatg ttccggatct gcatcgcagg atgctgctgg ctaccctgtg
3061 gaacacctac atctgtatta acgaagcgct ggcattgacc ctgagtgatt tttctctggt
3121 cccgccgcat ccataccgcc agttgtttac cctcacaacg ttccagtaac cgggcatgtt
3181 catcatcagt aacccgtatc gtgagcatcc tctctcgttt catcggtatc attaccccca
3241 tgaacagaaa tcccccttac acggaggcat cagtgaccaa acaggaaaaa accgccctta
3301 acatggcccg ctttatcaga agccagacat taacgcttct ggagaaactc aacgagctgg
3361 acgcggatga acaggcagac atctgtgaat cgcttcacga ccacgctgat gagctttacc
3421 gcagctgcct cgcgcgtttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccgg
3481 agacggtcac agcttgtctg taagcggatg ccgggagcag acaagcccgt cagggcgcgt
3541 cagcgggtgt tggcgggtgt cggggcgcag ccatgaccca gtcacgtagc gatagcggag
3601 tgtatactgg cttaactatg cggcatcaga gcagattgta ctgagagtgc accatatatg
3661 cggtgtgaaa taccgcacag atgcgtaagg agaaaatacc gcatcaggcg ctcttccgct
3721 tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac
3781 tcaaaggcgg taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga
3841 gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat
3901 aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac
3961 ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct
4021 gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg
4081 ctttctcata gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg
4141 ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt
4201 cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg
4261 attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac
4321 ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga
4381 aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt
4441 gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt
4501 tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaac
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4561 aataaaactg tctgcttaca taaacagtaa tacaaggggt gttatgagcc atattcaacg
4621 ggaaacgtct tgctctaggc cgcgattaaa ttccaacatg gatgctgatt tatatgggta
4681 taaatgggct cgcgataatg tcgggcaatc aggtgcgaca atctatcgat tgtatgggaa
4741 gcccgatgcg ccagagttgt ttctgaaaca tggcaaaggt agcgttgcca atgatgttac
4801 agatgagatg gtcagactaa actggctgac ggaatttatg cctcttccga ccatcaagca
4861 ttttatccgt actcctgatg atgcatggtt actcaccact gcgatccccg ggaaaacagc
4921 attccaggta ttagaagaat atcctgattc aggtgaaaat attgttgatg cgctggcagt
4981 gttcctgcgc cggttgcatt cgattcctgt ttgtaattgt ccttttaaca gcgatcgcgt
5041 atttcgtctc gctcaggcgc aatcacgaat gaataacggt ttggttgatg cgagtgattt
5101 tgatgacgag cgtaatggct ggcctgttga acaagtctgg aaagaaatgc ataaactttt
5161 gccattctca ccggattcag tcgtcactca tggtgatttc tcacttgata accttatttt
5221 tgacgagggg aaattaatag gttgtattga tgttggacga gtcggaatcg cagaccgata
5281 ccaggatctt gccatcctat ggaactgcct cggtgagttt tctccttcat tacagaaacg
5341 gctttttcaa aaatatggta ttgataatcc tgatatgaat aaattgcagt ttcatttgat
5401 gctcgatgag tttttctaag aattaattca tgagcggata catatttgaa tgtatttaga
5461 aaaataaaca aataggggtt ccgcgcacat ttccccgaaa agtgccacct aaattgtaag
5521 cgttaatatt ttgttaaaat tcgcgttaaa tttttgttaa atcagctcat tttttaacca
5581 ataggccgaa atcggcaaaa tcccttataa atcaaaagaa tagaccgaga tagggttgag
5641 tgttgttcca gtttggaaca agagtccact attaaagaac gtggactcca acgtcaaagg
5701 gcgaaaaacc gtctatcagg gcgatggccc actacgtgaa ccatcaccct aatcaagttt
5761 tttggggtcg aggtgccgta aagcactaaa tcggaaccct aaagggagcc cccgatttag
5821 agcttgacgg ggaaagccgg cgaacgtggc gagaaaggaa gggaagaaag cgaaaggagc
5881 gggcgctagg gcgctggcaa gtgtagcggt cacgctgcgc gtaaccacca cacccgccgc
5941 gcttaatgcg ccgctacagg gcgcgtccca ttcgcca
//

Appendix D. Control Vector: pET28-P1+GFP+His Sequencing Information
LOCUS

GS61233-2 pET28-control+GFP+His

5977 bp ds-DNA circular SYN 25-Apr-2017

DEFINITION .
ACCESSION .
VERSION

.

KEYWORDS

GS61233-2 pET28-control+GFP+His

SOURCE

synthetic DNA construct

ORGANISM synthetic DNA construct
REFERENCE 1 (bases 1 to 5977)
AUTHORS .
TITLE

Direct Submission

FEATURES

Location/Qualifiers
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source

1..5977
/organism="synthetic DNA construct"

/mol_type="other DNA"
terminator

26..73

/note="T7 terminator"
/note="transcription terminator for bacteriophage T7 RNA
polymerase"
/note="color: #ffffff"
CDS

complement(140..157)
/codon_start=1
/product="6xHis affinity tag"
/note="6xHis"
/note="color: #cc99b2"
/translation="HHHHHH"
misc_feature

173..949

/note="control+GFP+His"
/note="color: #a6acb3"
CDS

complement(179..892)
/codon_start=1
/product="GFP variant optimized for excitation by UV light"
/label="GFPuv"
/note="GFPuv"
/note="color: #05fd14"

/translation="MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLK
FICTTGKLPVPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDG
NYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQKNGIKA
NFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLE
FVTAAGITHGMDELYK"
protein_bind

952..976

/bound_moiety="lac repressor encoded by lacI"
/note="lac operator"
/note="The lac repressor binds to the lac operator to
inhibit transcription in E. coli. This inhibition can be
relieved by adding lactose or
isopropyl-beta-D-thiogalactopyranoside (IPTG)."
/note="color: #31849b"
promoter

complement(977..995)
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/note="T7 promoter"
/note="promoter for bacteriophage T7 RNA polymerase"
/note="color: #ffffff; direction: LEFT"
promoter

1304..1381

/gene="lacI"
/note="lacI promoter"
/note="
"
/note="color: #ffffff; direction: RIGHT"
CDS

1382..2464
/codon_start=1
/gene="lacI"
/product="lac repressor"
/note="lacI"
/note="The lac repressor binds to the lac operator to
inhibit transcription in E. coli. This inhibition can be
relieved by adding lactose or
isopropyl-beta-D-thiogalactopyranoside (IPTG)."
/note="color: #993366"

/translation="MKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAEL
NYIPNRVAQQLAGKQSLLIGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGV
EACKAAVHNLLAQRVSGLIINYPLDDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSH
EDGTRLGVEHLVALGHQQIALLAGPLSSVSARLRLAGWHKYLTRNQIQPIAEREGDWSA
MSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAITESGLRVGADISVVGYDDTEDSSC
YIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSLVKRKTTLAPNTQTASPR
ALADSLMQLARQVSRLESGQ"
CDS

3273..3464
/codon_start=1
/gene="rop"
/product="Rop protein"
/note="rop"
/note="color: #993366"

/translation="MTKQEKTALNMARFIRSQTLTLLEKLNELDADEQADICESLHDHA
DELYRSCLARFGDDGENL"
rep_origin

complement(3894..4482)

/direction=LEFT
/note="ori"
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/note="high-copy-number colE1/pMB1/pBR322/pUC origin of
replication"
/note="color: #ffff00"
CDS

4604..5419

/codon_start=1
/gene="aph(3')-Ia"
/product="aminoglycoside phosphotransferase"
/note="KanR"
/note="confers resistance to kanamycin"
/note="color: #ccffcc"
/translation="MSHIQRETSCSRPRLNSNMDADLYGYKWARDNVGQSGATIYRLYG
KPDAPELFLKHGKGSVANDVTDEMVRLNWLTEFMPLPTIKHFIRTPDDAWLLTTAIPGK
TAFQVLEEYPDSGENIVDALAVFLRRLHSIPVCNCPFNSDRVFRLAQAQSRMNNGLVDA
SDFDDERNGWPVEQVWKEMHKLLPFSPDSVVTHGDFSLDNLIFDEGKLIGCIDVGRVGI
ADRYQDLAILWNCLGEFSPSLQKRLFQKYGIDNPDMNKLQFHLMLDEFF"
rep_origin

complement(5511..5966)

/direction=LEFT
/note="f1 ori"
/note="f1 bacteriophage origin of replication; arrow
indicates direction of (+) strand synthesis"
/note="color: #ffff00"
ORIGIN
1 atccggatat agttcctcct ttcagcaaaa aacccctcaa gacccgttta gaggccccaa
61 ggggttatgc tagttattgc tcagcggtgg cagcagccaa ctcagcttcc tttcgggctt
121 tgttagcagc cggatctcag tggtggtggt ggtggtgctc gagtgcggcc gcaagctttt
181 tgtagagctc atccatgcca tgtgtaatcc cagcagcagt tacaaactca agaaggacca
241 tgtggtcacg cttttcgttg ggatctttcg aaagggcaga ttgtgtcgac aggtaatggt
301 tgtctggtaa aaggacaggg ccatcgccaa ttggagtatt ttgttgataa tggtctgcta
361 gttgaacgga tccatcttca atgttgtggc gaattttgaa gttagctttg attccattct
421 tttgtttgtc tgccgtgatg tatacattgt gtgagttata gttgtactcg agtttgtgtc
481 cgagaatgtt tccatcttct ttaaaatcaa taccttttaa ctcgatacga ttaacaaggg
541 tatcaccttc aaacttgact tcagcacgcg tcttgtagtt cccgtcatct ttgaaagata
601 tagtgcgttc ctgtacataa ccttcgggca tggcactctt gaaaaagtca tgccgtttca
661 tatgatccgg ataacgggaa aagcattgaa caccataaga gaaagtagtg acaagtgttg
721 gccatggaac aggtagtttt ccagtagtgc aaataaattt aagggtaagt tttccgtatg
781 ttgcatcacc ttcaccctct ccactgacag aaaatttgtg cccattaaca tcaccatcta
841 attcaacaag aattgggaca actccagtga aaagttcttc tcctttactc atgaattccg
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901 cgcaggtcca gcaatgatgt tcaatgcaat acgccacgca cattctagag gggaattgtt
961 atccgctcac aattccccta tagtgagtcg tattaatttc gcgggatcga gatctcgatc
1021 ctctacgccg gacgcatcgt ggccggcatc accggcgcca caggtgcggt tgctggcgcc
1081 tatatcgccg acatcaccga tggggaagat cgggctcgcc acttcgggct catgagcgct
1141 tgtttcggcg tgggtatggt ggcaggcccc gtggccgggg gactgttggg cgccatctcc
1201 ttgcatgcac cattccttgc ggcggcggtg ctcaacggcc tcaacctact actgggctgc
1261 ttcctaatgc aggagtcgca taagggagag cgtcgagatc ccggacacca tcgaatggcg
1321 caaaaccttt cgcggtatgg catgatagcg cccggaagag agtcaattca gggtggtgaa
1381 tgtgaaacca gtaacgttat acgatgtcgc agagtatgcc ggtgtctctt atcagaccgt
1441 ttcccgcgtg gtgaaccagg ccagccacgt ttctgcgaaa acgcgggaaa aagtggaagc
1501 ggcgatggcg gagctgaatt acattcccaa ccgcgtggca caacaactgg cgggcaaaca
1561 gtcgttgctg attggcgttg ccacctccag tctggccctg cacgcgccgt cgcaaattgt
1621 cgcggcgatt aaatctcgcg ccgatcaact gggtgccagc gtggtggtgt cgatggtaga
1681 acgaagcggc gtcgaagcct gtaaagcggc ggtgcacaat cttctcgcgc aacgcgtcag
1741 tgggctgatc attaactatc cgctggatga ccaggatgcc attgctgtgg aagctgcctg
1801 cactaatgtt ccggcgttat ttcttgatgt ctctgaccag acacccatca acagtattat
1861 tttctcccat gaagacggta cgcgactggg cgtggagcat ctggtcgcat tgggtcacca
1921 gcaaatcgcg ctgttagcgg gcccattaag ttctgtctcg gcgcgtctgc gtctggctgg
1981 ctggcataaa tatctcactc gcaatcaaat tcagccgata gcggaacggg aaggcgactg
2041 gagtgccatg tccggttttc aacaaaccat gcaaatgctg aatgagggca tcgttcccac
2101 tgcgatgctg gttgccaacg atcagatggc gctgggcgca atgcgcgcca ttaccgagtc
2161 cgggctgcgc gttggtgcgg atatctcggt agtgggatac gacgataccg aagacagctc
2221 atgttatatc ccgccgttaa ccaccatcaa acaggatttt cgcctgctgg ggcaaaccag
2281 cgtggaccgc ttgctgcaac tctctcaggg ccaggcggtg aagggcaatc agctgttgcc
2341 cgtctcactg gtgaaaagaa aaaccaccct ggcgcccaat acgcaaaccg cctctccccg
2401 cgcgttggcc gattcattaa tgcagctggc acgacaggtt tcccgactgg aaagcgggca
2461 gtgagcgcaa cgcaattaat gtaagttagc tcactcatta ggcaccggga tctcgaccga
2521 tgcccttgag agccttcaac ccagtcagct ccttccggtg ggcgcggggc atgactatcg
2581 tcgccgcact tatgactgtc ttctttatca tgcaactcgt aggacaggtg ccggcagcgc
2641 tctgggtcat tttcggcgag gaccgctttc gctggagcgc gacgatgatc ggcctgtcgc
2701 ttgcggtatt cggaatcttg cacgccctcg ctcaagcctt cgtcactggt cccgccacca
2761 aacgtttcgg cgagaagcag gccattatcg ccggcatggc ggccccacgg gtgcgcatga
2821 tcgtgctcct gtcgttgagg acccggctag gctggcgggg ttgccttact ggttagcaga
2881 atgaatcacc gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaacg tctgcgacct
2941 gagcaacaac atgaatggtc ttcggtttcc gtgtttcgta aagtctggaa acgcggaagt
3001 cagcgccctg caccattatg ttccggatct gcatcgcagg atgctgctgg ctaccctgtg
3061 gaacacctac atctgtatta acgaagcgct ggcattgacc ctgagtgatt tttctctggt
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3121 cccgccgcat ccataccgcc agttgtttac cctcacaacg ttccagtaac cgggcatgtt
3181 catcatcagt aacccgtatc gtgagcatcc tctctcgttt catcggtatc attaccccca
3241 tgaacagaaa tcccccttac acggaggcat cagtgaccaa acaggaaaaa accgccctta
3301 acatggcccg ctttatcaga agccagacat taacgcttct ggagaaactc aacgagctgg
3361 acgcggatga acaggcagac atctgtgaat cgcttcacga ccacgctgat gagctttacc
3421 gcagctgcct cgcgcgtttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccgg
3481 agacggtcac agcttgtctg taagcggatg ccgggagcag acaagcccgt cagggcgcgt
3541 cagcgggtgt tggcgggtgt cggggcgcag ccatgaccca gtcacgtagc gatagcggag
3601 tgtatactgg cttaactatg cggcatcaga gcagattgta ctgagagtgc accatatatg
3661 cggtgtgaaa taccgcacag atgcgtaagg agaaaatacc gcatcaggcg ctcttccgct
3721 tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac
3781 tcaaaggcgg taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga
3841 gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat
3901 aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac
3961 ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct
4021 gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg
4081 ctttctcata gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg
4141 ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt
4201 cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg
4261 attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac
4321 ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga
4381 aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt
4441 gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt
4501 tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaac
4561 aataaaactg tctgcttaca taaacagtaa tacaaggggt gttatgagcc atattcaacg
4621 ggaaacgtct tgctctaggc cgcgattaaa ttccaacatg gatgctgatt tatatgggta
4681 taaatgggct cgcgataatg tcgggcaatc aggtgcgaca atctatcgat tgtatgggaa
4741 gcccgatgcg ccagagttgt ttctgaaaca tggcaaaggt agcgttgcca atgatgttac
4801 agatgagatg gtcagactaa actggctgac ggaatttatg cctcttccga ccatcaagca
4861 ttttatccgt actcctgatg atgcatggtt actcaccact gcgatccccg ggaaaacagc
4921 attccaggta ttagaagaat atcctgattc aggtgaaaat attgttgatg cgctggcagt
4981 gttcctgcgc cggttgcatt cgattcctgt ttgtaattgt ccttttaaca gcgatcgcgt
5041 atttcgtctc gctcaggcgc aatcacgaat gaataacggt ttggttgatg cgagtgattt
5101 tgatgacgag cgtaatggct ggcctgttga acaagtctgg aaagaaatgc ataaactttt
5161 gccattctca ccggattcag tcgtcactca tggtgatttc tcacttgata accttatttt
5221 tgacgagggg aaattaatag gttgtattga tgttggacga gtcggaatcg cagaccgata
5281 ccaggatctt gccatcctat ggaactgcct cggtgagttt tctccttcat tacagaaacg
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5341 gctttttcaa aaatatggta ttgataatcc tgatatgaat aaattgcagt ttcatttgat
5401 gctcgatgag tttttctaag aattaattca tgagcggata catatttgaa tgtatttaga
5461 aaaataaaca aataggggtt ccgcgcacat ttccccgaaa agtgccacct aaattgtaag
5521 cgttaatatt ttgttaaaat tcgcgttaaa tttttgttaa atcagctcat tttttaacca
5581 ataggccgaa atcggcaaaa tcccttataa atcaaaagaa tagaccgaga tagggttgag
5641 tgttgttcca gtttggaaca agagtccact attaaagaac gtggactcca acgtcaaagg
5701 gcgaaaaacc gtctatcagg gcgatggccc actacgtgaa ccatcaccct aatcaagttt
5761 tttggggtcg aggtgccgta aagcactaaa tcggaaccct aaagggagcc cccgatttag
5821 agcttgacgg ggaaagccgg cgaacgtggc gagaaaggaa gggaagaaag cgaaaggagc
5881 gggcgctagg gcgctggcaa gtgtagcggt cacgctgcgc gtaaccacca cacccgccgc
5941 gcttaatgcg ccgctacagg gcgcgtccca ttcgcca
//
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Appendix E. Cloning Reactions
Table 1. Sample Klenow Extension Reaction.

Reaction 1 (P1+TAG)

Reaction 2 (P1+GCG)

Klenow (NEB M0210S 2015) 0.5 µL

0.5 µL

Oligo 1 (F)

1 µL (1.36 µg)

1 µL (1.36 µg)

Oligo 2 (R)

1 µL (1.36 µg)

1 µL (1.36 µg)

10X NEB 2 Buffer (2016)

2.0 µL

2.0 µL

dNTPs (Promega 12/17)

6.6 µL

6.6 µL

ddH2O

8.85 µL

8.85 µL

Total Reaction Volume

20 µL

20 µL

Add EDTA (0.5M stock)

0.4 µL

0.4 µL

*Incubate reaction for 15 mins at 25℃
**End reaction by adding 0.4 µL of 0.5M EDTA and heating at 75℃ for 20 minutes

Table 2. Sample Insert Double Digestion Reaction.

DNA (insert, 1µg)

10 µL

10X NEB Buffer

5 µL

Restriction Enzyme 1: EcoRI-HF

1 µL

Restriction Enzyme 2: XbaI

1 µL

ddH2O

33 µL

Total Reaction Volume

50 µL

*Incubate reaction for 10 hours at 37℃.
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Table 3. Sample pET28b-GFP Double Digestion Reaction.

DNA (pET28b-GFP, 1 µg)

10 µL

Restriction Enzyme 1: EcoRI-HF

1 µL

Restriction Enzyme 2: XbaI

1 µL

10X NEB Buffer

5 µL

ddH2O

33 µL

Total Reaction Volume

50 µL

*Incubate reaction for 4 hours at 37℃.

Table 4. Sample Calf Intestinal Alkaline Phosphatase (CIP) Reaction for pET28b-GFP.

DNA (pET28b-GFP, 1 µg)

15 µL

10X Cutsmart Buffer

2 µL

CIP

0.5 µ

ddH2O

2.5 µL

Total Reaction Volume

20 µL

*Incubate reaction for 50 minutes at 37℃.

Table 5. Sample pET28b-GFP + Oligonucleotide Ligation Reaction.

pET28b-GFP (47.5 ng)

5 µL

Oligonucleotide (4.82 ng)

3.2 µL

T4 DNA Ligase

1 µL

T4 DNA Ligase Buffer

1 µL

Total Reaction Volume

10.2 µL

*Incubate reaction for 4 hours at 23℃
** Reaction shown is 1:10 pET28b-GFP:oligonucleotide. 1:1 and 1:2 reactions were also
performed.
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Appendix F. Project Expenses
Product

Cost

Sequencing

$156

L-arabinose

$61

Oligonucleotides

$118.12

L-DOPA

$51.90

Cloning

$535

Total

$922.02
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Appendix G. Project Timeline

Figure 4. Project Timeline.
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